✦ LIBER ✦

Oxiracetam in the treatment of primary dementia of the Alzheimer's type: A small case series

✍ Scribed by Stephen R. Dager; J. Pierre Loebel; Keith Claypool; Mary Case; Christopher B. Budech; David L. Dunner

Publisher: John Wiley and Sons
Year: 1992
Tongue: English
Weight: 602 KB
Volume: 7
Category: Article
ISSN: 0885-6230
DOI: 10.1002/gps.930071210

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

A 16‐week open‐label trial of high‐dose oxiracetam (up to 3200 mg per day), was not clinically effective overall in treating a small cohort of patients with mild‐moderate dementia of the Alzheimer's type (DAT). However, one of six patients did demonstrate evidence of progressive clinical improvement followed by relapse after discontinuation of medication. Resumption of treatment with oxiracetam after a 6‐month interval was associated with a similar pattern of improvement on neuropsychological testing and enhanced social functioning which was sustained during an additional 5 years of treatment. Following death due to unrelated causes, brain histopathologic findings were consistent with late‐stage DAT despite the patient's sustained clinical improvement while under treatment with oxiracetam.

📜 SIMILAR VOLUMES

The effectiveness of amiridin in senile

The effectiveness of amiridin in senile dementia of the Alzheimer's type

✍ E. E. Bukatina; I. V. Grigor'eva; E. I. Sokol'chik 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 590 KB

Reliability of flicker threshold measure

Reliability of flicker threshold measurement in patients with primary degenerative dementia of the Alzheimer's type (PDDAT)

✍ Dr. S. Curran; J. P. Wattis; I. Hindmarch 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 455 KB 👁 1 views

The test-retest and split-half ,reliability of flicker threshold measurement was determined in 23 female and three male patients with primary degenerative dementia of the Alzheimer's type (PDDAT). Patients had a mean age of 81.7 f 6.05 years (range 67-89). Diagnosis of PDDAT was based on DSM-IIIR cr

Glucose metabolism as the site of the pr

Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type?

✍ S. Hoyer; K. Oesterreich; O. Wagner 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 647 KB

Global cerebral blood flow, oxidative brain metabolism, and the cerebral arteriovenous differences of amino acids and ammonia were studied in 20 clinically diagnosed patients with early-onset dementia of Alzheimer type (DAT). Eleven healthy age-matched subjects and 15 healthy young volunteers served

Averting Dementia of the Alzheimer's Typ

Averting Dementia of the Alzheimer's Type in Women: Can Counselors Help?

✍ Kathryn Z. Douthit 📂 Article 📅 2007 🏛 American Counseling Association 🌐 English ⚖ 178 KB

Alzheimer's disease (AD) is the most common cause of dementia in late life, taking its greatest toll on women over age 80. This article provides an overview of AD, including risk factors and counseling strategies targeting risk. Counseling strategies address stress, cardiovascular health, social int

Towards a clinically specific profile of

Towards a clinically specific profile of severe senile primary degenerative dementia of the Alzheimer type (PDDAT)

✍ H. Stuckstedte; C. -M. Abrahams; G. Ulmar 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 78 KB

Concurrent validity of critical flicker

Concurrent validity of critical flicker fusion in patients with primary degenerative dementia of the Alzheimer type

✍ Stephen Curran; John P. Wattis; Ian Hindmarch 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 576 KB

The concurrent validity of critical flicker fusion threshold (CFFT) and flicker threshold measurement was examined in 23 female and three male patients with primary degenerative dementia of the Alzheimer type (PDDAT). Patients had a mean age of 8 1.7 6.05 years (range 67-89). Diagnosis of PDDAT was